Active, not recruitingPhase 2NCT05581199
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immunovant Sciences GmbH
- Intervention
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly(drug)
- Enrollment
- 277 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Site Number - 1603, Scottsdale, Arizona, United States
- Site Number - 1618, Carlsbad, California, United States
- Site Number - 1634, Los Angeles, California, United States
- Site Number - 1619, Orange, California, United States
- Site Number - 1608, San Francisco, California, United States
- Site Number - 1625, Aurora, Colorado, United States
- Site Number - 1636, Fort Collins, Colorado, United States
- Site Number - 1621, New Haven, Connecticut, United States
- Site Number - 1630, Washington D.C., District of Columbia, United States
- Site Number - 1600, Boca Raton, Florida, United States
- Site Number - 1609, Jacksonville, Florida, United States
- Site Number - 1631, Orlando, Florida, United States
- Site Number - 1629, Orlando, Florida, United States
- Site Number - 1617, Ormond Beach, Florida, United States
- Site Number - 1620, Port Charlotte, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05581199 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →